# A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma

> **NCT00967330** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 182 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** irinotecan
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00967330
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967330, "A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00967330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*